NCT01518322View on ClinicalTrials.gov

Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms

CompletedOBSERVATIONAL
Enrollment

235

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Asthma
Interventions
DEVICE

NIOX MINO®

Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®

Trial Locations (13)

55901

Olmstead Medical Center Northwest, Rochester

55904

Olmstead Medical Center - Allergy Department, Rochester

Olmstead Medical Center - Family Medicine Department, Rochester

Olmsted Medical Center - Internal Medicine Department, Rochester

55920

Olmstead Medical Center Byron, Byron

55923

Olmstead Medical Center Chatfield, Chatfield

55963

Olmstead Medical Center Pine Island, Pine Island

55964

Olmstead Medical Center Plainview, Plainview

55965

Olmstead Medical Center Preston, Preston

55972

Olmstead Medical Center St. Charles, Saint Charles

55975

Olmstead Medical Center Spring Valley, Spring Valley

55976

Olmstead Medical Center Stewartville, Stewartville

55983

Olmstead Medical Center Wanamingo, Wanamingo

Sponsors

Lead Sponsor

Aerocrine AB
All Listed Sponsors
lead

Aerocrine AB

INDUSTRY

NCT01518322 - Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms | Biotech Hunter | Biotech Hunter